Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

被引：66

作者：

Rea, Delphine ^{[1
]}

Ame, Shanti ^{[1
]}

Berger, Marc ^{[1
]}

Cayuela, Jean-Michel ^{[1
]}

Charbonnier, Aude ^{[1
]}

Coiteux, Valerie ^{[1
]}

Cony-Makhoul, Pascale ^{[1
]}

Dubruille, Viviane ^{[1
]}

Dulucq, Stephanie ^{[1
]}

Etienne, Gabriel ^{[1
]}

Legros, Laurence ^{[1
]}

Nicolini, Franck ^{[1
]}

Roche-Lestienne, Catherine ^{[1
]}

Escoffre-Barbe, Martine ^{[1
]}

Gardembas, Martine ^{[1
]}

Guerci-Bresler, Agnes ^{[1
]}

Johnson-Ansah, Hyacinthe ^{[1
]}

Rigal-Huguet, Francoise ^{[1
]}

Rousselot, Philippe ^{[1
]}

Mahon, Francois-Xavier ^{[1
]}

机构：

[1] Bergonie Inst, French Chron Myeloid Leukemia Study Grp, Bordeaux, France

来源：

CANCER | 2018年 / 124卷 / 14期

关键词：

chronic myeloid leukemia; clinical practice; recommendations; treatment discontinuation; tyrosine kinase inhibitors; TREATMENT-FREE REMISSION; DEEP MOLECULAR RESPONSE; IMATINIB CESSATION; CML PATIENTS; MANAGEMENT; RELAPSE; IMPACT; DASATINIB; NILOTINIB; DISEASE;

D O I：

10.1002/cncr.31411

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is called treatment-free remission (TFR). Knowledge accumulated during the last 10 years justifies moving TFR strategies from research to clinical practice.METHODS: Twenty experts from the French Chronic Myeloid Leukemia Study Group (France Intergroupe des Leucemies Myeloides Chroniques), including 17 hematologists, 2 molecular biologists, and 1 cytogeneticist, critically reviewed published data with the goal of developing evidence-based recommendations for TKI discontinuation in clinical practice.RESULTS: Clinically relevant questions were addressed, including the selection of candidate patients (with known prognostic factors for outcomes taken into account), detailed monitoring procedures during the treatment-free phase, a definition of relapse requiring therapy resumption, and monitoring after treatment reintroduction.CONCLUSIONS: This work presents consensus statements with the aim of guiding physicians and biologists by means of pragmatic recommendations for safe TKI discontinuation in daily practice. (C) 2018 American Cancer Society.

引用

页码：2956 / 2963

页数：8

共 42 条

[1]

Alikian Mary, 2017, Biomol Detect Quantif, V11, P4, DOI 10.1016/j.bdq.2017.01.001

[2] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[3] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[4] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[5] Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [J].

Bower, Hannah ;

Bjorkholm, Magnus ;

Dickman, Paul W. ;

Hoglund, Martin ;

Lambert, Paul C. ;

Andersson, Therese M. -L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2851-+

[6] BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management [J].

Branford, Susan ;

Yeung, David T. ;

Prime, Jodi A. ;

Choi, Soo-Young ;

Bang, Ju-hee ;

Park, Jin Eok ;

Kim, Dong-Wook ;

Ross, David M. ;

Hughes, Timothy P. .

BLOOD, 2012, 119 (18) :4264-4271

[7] Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia [J].

Cross, N. C. P. ;

White, H. E. ;

Colomer, D. ;

Ehrencrona, H. ;

Foroni, L. ;

Gottardi, E. ;

Lange, T. ;

Lion, T. ;

Polakova, K. Machova ;

Dulucq, S. ;

Martinelli, G. ;

Leibundgut, E. Oppliger ;

Pallisgaard, N. ;

Barbany, G. ;

Sacha, T. ;

Talmaci, R. ;

Izzo, B. ;

Saglio, G. ;

Pane, F. ;

Mueller, M. C. ;

Hochhaus, A. .

LEUKEMIA, 2015, 29 (05) :999-1003

[8] Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia [J].

Etienne, Gabriel ;

Guilhot, Joelle ;

Rea, Delphine ;

Rigal-Huguet, Francoise ;

Nicolini, Franck ;

Charbonnier, Aude ;

Guerci-Bresler, Agnes ;

Legros, Laurence ;

Varet, Bruno ;

Gardembas, Martine ;

Dubruille, Viviane ;

Tulliez, Michel ;

Noel, Marie-Pierre ;

Ianotto, Jean-Christophe ;

Villemagne, Bruno ;

Carre, Martin ;

Guilhot, Francois ;

Rousselot, Philippe ;

Mahon, Francois-Xavier .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (03) :298-+

[9] Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase [J].

Goldman, John M. ;

Majhail, Navneet S. ;

Klein, John P. ;

Wang, Zhiwei ;

Sobocinski, Kathleen A. ;

Arora, Mukta ;

Horowitz, Mary M. ;

Rizzo, J. Douglas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1888-1895

[10] Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party [J].

Gugliotta, Gabriele ;

Castagnetti, Fausto ;

Palandri, Francesca ;

Breccia, Massimo ;

Intermesoli, Tamara ;

Capucci, Adele ;

Martino, Bruno ;

Pregno, Patrizia ;

Rupoli, Serena ;

Ferrero, Dario ;

Gherlinzoni, Filippo ;

Montefusco, Enrico ;

Bocchia, Monica ;

Tiribelli, Mario ;

Pierri, Ivana ;

Grifoni, Federica ;

Marzocchi, Giulia ;

Amabile, Marilina ;

Testoni, Nicoletta ;

Martinelli, Giovanni ;

Alimena, Giuliana ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Baccarani, Michele ;

Rosti, Gianantonio .

BLOOD, 2011, 117 (21) :5591-5599

← 1 2 3 4 5 →